NextFin News - The U.S. Food and Drug Administration has approved a high-dose version of Novo Nordisk’s blockbuster obesity drug Wegovy, a move that significantly raises the ceiling for weight loss efficacy in the semaglutide franchise. The 7.2 mg weekly injection, approved on Thursday, represents a tripling of the previous 2.4 mg maximum dose. This regulatory milestone was achieved through a specialized expedited review program established under FDA Commissioner Marty Makary, utilizing a "National Priority Voucher" that Novo Nordisk secured following a landmark pricing agreement with U.S. President Trump’s administration late last year.
The approval is anchored by data from the STEP UP phase 3 clinical trial, which demonstrated that patients without diabetes taking the 7.2 mg dose achieved an average weight loss of 20.7% over 72 weeks. This figure is a notable jump from the 17.5% loss observed in the 2.4 mg cohort and the 2.4% seen in the placebo group. Perhaps more critically for Novo’s competitive positioning, one-third of participants on the high dose lost at least 25% of their body weight, a threshold previously dominated by Eli Lilly’s dual-agonist therapy, Zepbound.
For Novo Nordisk, the timing is as much about market defense as it is about clinical advancement. After being the first to ignite the modern obesity market, the Danish drugmaker has spent the last year watching Eli Lilly erode its dominance. Lilly’s tirzepatide has consistently shown superior weight-loss percentages in head-to-head comparisons, leading to a shift in prescriber preference toward the more potent "twincretin" mechanism. By pushing semaglutide to a 7.2 mg concentration, Novo is attempting to prove that its single-hormone GLP-1 backbone can still match the results of more complex multi-receptor molecules.
The trade-off for this increased potency appears to be a higher burden of side effects. Clinical data indicated that gastrointestinal adverse events were more frequent with the 7.2 mg dose than with the standard 2.4 mg version. While serious adverse events remained relatively low at 6.8%, the tolerability of such a high dose in a real-world setting—where patients may not have the same titration support as trial participants—remains a key variable for long-term adoption. Novo is betting that for a specific segment of the "non-responder" population, the promise of 20%-plus weight loss will outweigh the risk of nausea or vomiting.
The approval also highlights the evolving relationship between the pharmaceutical industry and the Trump administration. The use of the National Priority Voucher, a mechanism intended to fast-track drugs that align with federal health goals, suggests a transactional shift in how the FDA operates under the current executive branch. Novo’s willingness to lower prices in exchange for regulatory speed has allowed it to bring this high-dose variant to market months ahead of initial analyst expectations, providing a much-needed catalyst for a stock that has struggled to keep pace with its American rival.
Supply chain resilience will be the final hurdle. Novo Nordisk has spent billions expanding its manufacturing footprint to resolve the chronic shortages that defined the early years of the Wegovy launch. The introduction of a 7.2 mg dose adds complexity to an already strained production line, particularly as the company also seeks approval for a single-dose delivery device. Whether Novo can satisfy the inevitable surge in demand for this "extra-strength" Wegovy will determine if this approval marks a true turning point or merely a temporary reprieve in the battle for the $100 billion obesity market.
Explore more exclusive insights at nextfin.ai.
